Key result
Anti-Ro/SSA antibodies elevated the risk of severe mitral regurgitation in patients with systemic lupus erythematosus compared to antibody-negative patients.
Why the study?
Does anti-Ro/SSA antibody positivity increase the risk of severe mitral valve regurgitation in patients with systemic lupus erythematosus?
Observational (n=89)
No
Does anti-Ro/SSA antibody positivity increase the risk of severe mitral valve regurgitation in patients with systemic lupus erythematosus?
Anti-Ro/SSA antibodies, particularly against Ro52/TRIM21, are associated with a significantly increased risk of severe mitral valve regurgitation in patients with systemic lupus erythematosus.
Answers are grounded in this paper and cite their sources.
Association of anti-Ro/SSA with valvular disease in lupus is hypothesis-generating; larger prospective studies needed to confirm.
OBJECTIVE: To assess whether anti-Ro/SSA antibodies are associated with cardiac valve disease in lupus. METHODS: A single-center, medical chart review was performed. Lupus patients were divided according to its anti-Ro/SSA status and subgroups were compared for valvular abnormalities and other characteristics. Dependence of anti-Ro/SSA reactivity to anti-Ro52/TRIM21 antibodies was also evaluated. RESULTS: Eighty-nine lupus patients were analyzed. The most common valvular abnormalities were tricuspid (60%), mitral (41%) and pulmonary (14%) regurgitation. Thirty-six patients were positive and 53 negative for anti-Ro/SSA antibodies. In patients positive to anti-Ro/SSA, a difference was noted for anti-dsDNA (67 versus 45%; p = 0.04) and anti-La/SSB (19 versus 2%; p = 0.004) antibodies. An association between anti-Ro/SSA antibodies and severe mitral regurgitation was observed; indeed, 4/15 patients with anti-Ro/SSA and mitral regurgitation had severe forms of valvulopathy as compared to only 1/22 patients with mitral regurgitation but negative to such antibody (27 versus 5%; p = 0.02). Anti-Ro/SSA antibodies significantly elevated the risk of severe mitral regurgitation (OR = 5). Anti-Ro52/TRIM21 levels (103 ± 29 versus 42 ± 43 U/mL; p = 0.03) and anti-Ro52/TRIM21: anti-Ro/SSA ratios (0.88 ± 0.02 versus 0.35 ± 0.37; p = 0.03) were higher in patients with mitral valve regurgitation than in those with no valvulopathy. CONCLUSION: Anti-Ro/SSA antibodies, mainly against Ro52/TRIM21 antigens, may be pathologically involved in lupus-associated mitral valve regurgitation.
No takes yet. Share an insight, caveat, or question.
Higuera‐Ortiz et al. (2016) conducted an observational in Systemic lupus erythematosus (n=89). Anti-Ro/SSA antibodies vs. Negative for anti-Ro/SSA antibodies was evaluated on Severe mitral regurgitation (OR 5, p=0.02). Anti-Ro/SSA antibodies elevated the risk of severe mitral regurgitation in patients with systemic lupus erythematosus compared to antibody-negative patients.
Synapse has enriched 10 related papers. Consider them for comparative context: